WO2005115456A3 - METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY - Google Patents

METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY Download PDF

Info

Publication number
WO2005115456A3
WO2005115456A3 PCT/US2005/018790 US2005018790W WO2005115456A3 WO 2005115456 A3 WO2005115456 A3 WO 2005115456A3 US 2005018790 W US2005018790 W US 2005018790W WO 2005115456 A3 WO2005115456 A3 WO 2005115456A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
methods
endocrine system
tnfαactivity
modulation
Prior art date
Application number
PCT/US2005/018790
Other languages
French (fr)
Other versions
WO2005115456A2 (en
WO2005115456A9 (en
Inventor
Adrian Erlebacher
Laurie H Glimcher
Original Assignee
Harvard College
Adrian Erlebacher
Laurie H Glimcher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Adrian Erlebacher, Laurie H Glimcher filed Critical Harvard College
Publication of WO2005115456A2 publication Critical patent/WO2005115456A2/en
Publication of WO2005115456A9 publication Critical patent/WO2005115456A9/en
Publication of WO2005115456A3 publication Critical patent/WO2005115456A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides treatment methods, as well as prognostic and diagnostic methods of modulating the reproductive-endocrine system, e.g., inhibiting spontaneous abortion, by modulating TNF-α expression and/or activity.
PCT/US2005/018790 2004-05-28 2005-05-27 METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY WO2005115456A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57514304P 2004-05-28 2004-05-28
US60/575,143 2004-05-28

Publications (3)

Publication Number Publication Date
WO2005115456A2 WO2005115456A2 (en) 2005-12-08
WO2005115456A9 WO2005115456A9 (en) 2006-01-26
WO2005115456A3 true WO2005115456A3 (en) 2006-05-18

Family

ID=35451413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018790 WO2005115456A2 (en) 2004-05-28 2005-05-27 METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY

Country Status (1)

Country Link
WO (1) WO2005115456A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
GB201314452D0 (en) * 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARP H. ET AL: "Hormones, cytokines and fetal anomalies in habitual abortion", GYNECOLOGICAL ENDOCRINOLOGY, vol. 15, no. 6, 1 December 2001 (2001-12-01), pages 472 - 483, XP008058014 *

Also Published As

Publication number Publication date
WO2005115456A2 (en) 2005-12-08
WO2005115456A9 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
WO2005021025A3 (en) MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2004018058A3 (en) Compounds, compositions, and methods
WO2006042206A3 (en) Systems and methods for direct restoration of foraminal volume
WO2005082115A3 (en) Bone plates with locking apertures
EP1764049A3 (en) Anterior Cervical Plating System
WO2007047781A3 (en) Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2005117938A3 (en) Methods of treating ocular conditions
WO2006122156A3 (en) Compounds for modulating trpv3 function
WO2007056124A3 (en) Compounds for modulating trpv3 function
EP1263765A4 (en) ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
WO2005107762A3 (en) Certain chemical entities, compositions, and methods
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2007145875A3 (en) Data coding
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2006031926A3 (en) Methods for the isolation and expansion of cord blood derived t regulatory cells
TW200729800A (en) In-band rate control for an orthogonal frequency division multiple access communication system
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
WO2005074645A3 (en) Methods and compositions for modulating angiogenesis
WO2005049802A3 (en) Anti-hydroxylase antibodies and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase